[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614791":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":122,"collaborators":11,"id":124,"slug":11,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":11,"eligibilityCriteria":129,"healthyVolunteers":125,"sex":130,"minAge":131,"maxAge":11,"enrollmentInfo":132,"targetDuration":11,"studyType":135,"phases":136,"briefSummary":138,"conditions":139,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Plexium, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PLX-61639","EXPERIMENTAL",null,[13],"Drug: PLX-61639",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Orally available degrader of SMARCA2",[9],[20],{"name":21,"affiliation":5,"role":22},"Chief Medical Officer","STUDY_DIRECTOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Clinical Operations","CONTACT","619-631-3091","ClinicalTrials@Plexium.com",[30,43,52,60,69,78,86,95,104,113],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":11},"Research Site","RECRUITING","Scottsdale","Arizona","85258","United States",{"type":38,"coordinates":39},"Point",[40,41],-111.89903,33.50921,{"lat":41,"lon":40},{"facility":31,"status":32,"city":44,"state":45,"zip":46,"country":36,"cosmosGeoPoint":47,"geoPoint":51,"contacts":11},"Duarte","California","91010",{"type":38,"coordinates":48},[49,50],-117.97729,34.13945,{"lat":50,"lon":49},{"facility":31,"status":32,"city":53,"state":45,"zip":54,"country":36,"cosmosGeoPoint":55,"geoPoint":59,"contacts":11},"Orange","92868",{"type":38,"coordinates":56},[57,58],-117.85311,33.78779,{"lat":58,"lon":57},{"facility":31,"status":32,"city":61,"state":62,"zip":63,"country":36,"cosmosGeoPoint":64,"geoPoint":68,"contacts":11},"Boston","Massachusetts","02114",{"type":38,"coordinates":65},[66,67],-71.05977,42.35843,{"lat":67,"lon":66},{"facility":31,"status":32,"city":70,"state":71,"zip":72,"country":36,"cosmosGeoPoint":73,"geoPoint":77,"contacts":11},"St Louis","Missouri","63110",{"type":38,"coordinates":74},[75,76],-90.19789,38.62727,{"lat":76,"lon":75},{"facility":31,"status":32,"city":79,"state":79,"zip":80,"country":36,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"New York","10044",{"type":38,"coordinates":82},[83,84],-74.00597,40.71427,{"lat":84,"lon":83},{"facility":31,"status":32,"city":87,"state":88,"zip":89,"country":36,"cosmosGeoPoint":90,"geoPoint":94,"contacts":11},"Durham","North Carolina","27710",{"type":38,"coordinates":91},[92,93],-78.89862,35.99403,{"lat":93,"lon":92},{"facility":31,"status":32,"city":96,"state":97,"zip":98,"country":36,"cosmosGeoPoint":99,"geoPoint":103,"contacts":11},"Cleveland","Ohio","44106",{"type":38,"coordinates":100},[101,102],-81.69541,41.4995,{"lat":102,"lon":101},{"facility":31,"status":32,"city":105,"state":106,"zip":107,"country":36,"cosmosGeoPoint":108,"geoPoint":112,"contacts":11},"San Antonio","Texas","78229",{"type":38,"coordinates":109},[110,111],-98.49363,29.42412,{"lat":111,"lon":110},{"facility":31,"status":32,"city":114,"state":115,"zip":116,"country":36,"cosmosGeoPoint":117,"geoPoint":121,"contacts":11},"Fairfax","Virginia","22031",{"type":38,"coordinates":118},[119,120],-77.30637,38.84622,{"lat":120,"lon":119},{"type":123,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100614791",false,"NCT07284186","First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors","A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Participants with locally advanced or metastatic, relapsed\u002Frefractory, solid tumors harboring a SMARCA4 loss-of-function mutation that have progressed on, are intolerant of, or not otherwise candidates for available approved therapies\n* Adequate liver bone marrow, coagulation, renal, and cardiopulmonary function\n* Measurable disease per RECIST 1.1\n* ECOG PS of 0 or 1\n\nKey Exclusion Criteria:\n\n* Germline SMARCA4 mutations\n* Known SMARCA2 mutation or loss of expression\n* Symptomatic CNS disease\n* Prior treatment with another SMARCA2-directed therapy\n* History of other malignancies\n* Clinically significant heart disease\n* Uncontrolled hypertension\n* Prolongation of QT interval","ALL","18 Years",{"count":133,"type":134},155,"ESTIMATED","INTERVENTIONAL",[137],"PHASE1","A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed\u002Frefractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, approved therapies.\n\nThe study will be conducted in 3 parts: dose escalation (Part 1), dose optimization (Part 2), and cohort expansion (Part 3). Each part of the study will consist of a Screening Phase lasting up to 28 days during which participants will be assessed for eligibility, a Treatment Phase beginning on Cycle 1 Day 1 and consisting of consecutive 28-day cycles, an End of Treatment Visit, and a Post-Treatment Follow-Up Phase.\n\nParticipants will receive their assigned dose of PLX-61639 administered orally, once daily until progression\u002Frelapse, intolerance, death, or withdrawal from study treatment by the Investigator or participant.",[140,141,142,143,144,145,146,147,148,149],"Esophageal Squamous Cell Carcinoma","Gastric Adenocarcinoma","Gastric Squamous Cell Carcinoma","Gastroesophageal Junction (GEJ) Adenocarcinoma","Metastatic Solid Tumor","Non-Small Cell Lung Carcinoma","Esophageal Adenocarcinoma","SMARCA4 Mutation","Gastroesophageal Junction Squamous Cell Carcinoma","Advanced Solid Tumor","2026-06-10",{"date":152,"type":153},"2026-06-12","ACTUAL",{"date":155,"type":153},"2025-12-01",{"date":157,"type":134},"2030-09",{"name":5,"class":6},10]